PHILADELPHIA--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB), a company focused on biotechnology solutions that address the unmet medical needs of seriously debilitating disorders and pandemic viral threats, announced today that the Company will hold a conference call for investors and interested parties on Tuesday, May 1, 2007, at 4:15 pm. The call will focus on the financial results for the fiscal year ended December 31, 2006; the ongoing New Drug Application (NDA) activities for Hemispherx’s experimental therapeutic, Ampligen®, for the potential treatment of Chronic Fatigue Syndrome; new developments in Hemispherx’s initiative in Japan addressing the pandemic threat of influenza; and ongoing commercialization initiatives.
